Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 5Breast Neoplasms 4Brain Neoplasms 3von Hippel-Lindau Disease 1Tonsillar Neoplasms 1Solid Tumor 1Sarcoma 1Prostatic Neoplasms 1Pharyngeal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Optic Nerve Diseases 1Neoplastic Cells, Circulating 1Hemangioblastoma 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Primary Liver Cancer 1

Interventions

lenvatinib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Advanced Primary Liver Cancer × Bevacizumab × Clear all
NCT05411757 2022-06-09

IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

Shandong Public Health Clinical Center

Phase EARLY_PHASE1 Unknown
12 enrolled

Advanced Primary Liver Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡